When outcome selection and prioritisation are defined early in development, the evidence base supports continuity from trial ...
Perspective Therapeutics, Inc. (NYSE:CATX) has announced encouraging interim results from its ongoing Phase 1/2a clinical trial of [212Pb]VMT-α-NET, a targeted radiopharmaceutical for patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results